London, July 3, 2026, 09:24 BST
- Proteome Sciences plc (LON:PRM) jumped 38.79% as of 09:05 BST, trading on a 1.30p/2.30p sell-buy spread.
- AJ Bell logged 20 shares traded. PRM led the FTSE AIM All-Share risers, according to its table.
- Investegate showed no PRM RNS more recent than June 22. The last update was about a clinical chemoproteomics contract.
- The 2025 mix switched sharply. Services revenue jumped 2.4 times to £2.06 million. TMT sales and royalties dropped 58% to £1.70 million.
Proteome Sciences plc (LON:PRM) was the top gainer on AIM early Friday, but trading was thin. AJ Bell quoted the stock at 2.29p, up 0.64p, or 38.79%, on just 20 shares traded. The sell price was 1.30p, buy at 2.30p, leaving a spread of 1.00p, or around 56% of the midpoint.
London shares were trading at the time. Fidelity’s AIM index page lists regular LSE hours as 8 a.m. to 4.30 p.m. Monday to Friday, excluding holidays. London clock showed 09:24 BST.
| Friday morning trade | Proteome Sciences | FTSE AIM All-Share |
|---|---|---|
| Last price/quote | 2.29p / buy at 2.30p | 777.98 |
| Day move | up 38.79% | up 0.07% |
| Prev close | 1.65p | 777.45 |
| Volume reported | 20 shares | n/a |
| Rank shown | Top AIM mover | Benchmark |
The price move added about £2.2 million in equity value based on the company’s 350.7 million shares after its January fundraise. At the session high of 2.30p, just 20 shares changed hands, with a cash value of around 46 pence. The annual report showed 350,724,912 ordinary shares outstanding post-fundraise.
No new RNS from the company were posted in the last 24 to 48 hours on the main PRM feeds checked. Investegate’s PRM page still showed June 22 as the latest RNS, after June 1 directorate changes and some AGM items in May. The company’s news page also listed June 22 as the most recent release.
Proteome said on June 22 it picked up another major clinical contract linked to its target engagement and chemoproteomics platform. The company said the deal could set up a new clinical trial program in 2026. Executive Chairman Christopher Pearce said the contract points to “momentum and growth” in chemoproteomics services following interest at the ASMS event in San Diego.
The real test for investors is if services can cover the drop in TMT revenue. Services overtook TMT as the bigger line in 2025, but total revenue still dropped.
| 2025 financial line | 2025 | 2024 | Change |
|---|---|---|---|
| Group revenue | £3.76 mln | £4.89 mln | -23% |
| Services revenue | £2.06 mln | £0.87 mln | 2.4x |
| Services share of revenue | 55% | 18% | +37 pts |
| TMT sales and royalties | £1.70 mln | £4.01 mln | -58% |
| Adjusted EBITDA loss | £1.72 mln | £1.48 mln | Loss widened |
| Loss after tax | £3.06 mln | £3.41 mln | Loss narrowed |
| Year-end cash | £0.78 mln | £1.13 mln | Down |
Pearce wrote in the annual report that 2025 is “the bottom of the cycle for our business.” Management expects services to grow and TMT reagents to bounce back after the reagents business hurt group cash flow, which forced the company into a share placing and retail offer in January 2026.
The risk here is that ramping up services depends on landing orders, not just having capacity in place. Proteome itself said in its risk section that it’s not clear if contract proteomic services will bring in enough revenue given the competition. The company also said opening its U.S. lab means there’s now a higher risk of too few orders to make the business profitable.
